NCT02163018View on ClinicalTrials.gov

HAL-MPE1 First-in-human

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions

Peanut Allergy

Interventions

DRUG

HAL-MPE1

Subcutaneous administration of increasing doses of HAL-MPE1

DRUG

Placebo

Subcutaneous administration of increasing doses of placebo

Trial Locations (1)

DK 5000

Carsten Bindslev-Jensen, Odense

Sponsors

Lead Sponsor

All Listed Sponsors

lead

HAL Allergy

INDUSTRY